• Genetic counselling and genetic medicine in clinical practice in Spain
  C. Ayuso
   
• Organisation of the new profession and the new masters of genetic counselling in France
  N. Philip
   
• Risk communication of in Fragile-X
  A. McConkie-Rosell

EPL1.1 Recall and interpretation in genetic counselling, after intake and non-informative DNA-test results in BRCA1/2: discrepancies, explanations and consequences
J. Vos¹, C. J. Van Asperen¹, J. C. Oosterwijk², E. B. Gomez Garcia³, F. H. Menko⁴, J. M. Collee⁵, A. M. Stiggelbout⁶, A. Tibben¹;
¹Leiden University Medical Center, Center of Human and Clinical Genetics, dep. of Clinical Genetics, Leiden, The Netherlands, ²University Hospital Groningen, dep. of clinical genetics, Groningen, The Netherlands, ³Maastricht University Medical Center, dep. of clinical genetics, Maastricht, The Netherlands, ⁴VU University Medical Center, dep. of clinical genetics, Amsterdam, The Netherlands, ⁵Erasmus Medical Center Rotterdam, dep. of clinical genetics, Rotterdam, The Netherlands, ⁶Leiden University Medical Center, dep. of Medical Decision Making, Leiden, The Netherlands.

EPL1.2 Is enhanced information at genetic counselling necessary?- a randomised study
A. Roshanai¹, R. Rosenquist², K. Nordin¹;
¹Department of Public Health and Caring Sciences, Uppsala, Sweden, ²Department of Genetics and Pathology, Uppsala, Sweden.

EPL1.3 Determining the genetic status of women newly diagnosed with breast cancer prior to treatment decisions: An ethical challenge
E. A. Lobb^1,2, N. Hallowell³, K. Barlow-Stewart⁴, G. Suthers⁵;
¹Medical Psychology Research Unit, University of Sydney, Camperdown, Australia, ²WA Centre for Cancer & Palliative Care, Curtin University of Technology, Perth, Australia, ³Public Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom, ⁴Centre for Genetics Education, Royal North Shore Hospital, St Leonards, Australia, ⁵Familial Cancer Unit, Department of Genetic Medicine, Children’s Youth & Women’s Health Service, Adelaide, Australia.

EPL1.4 Impact of using family history on motivation to prevent type 2 diabetes: an RCT
M. Pijl^1,2, D. R. M. Timmermans^1,2, L. Claassen^1,2, A. C. J. W. Janssens³, G. Nijpels^1,4, T. M. Marteau⁵, L. Henneman^1,2;
¹Department of Public and Occupational Health, VU University Medical Center, Amsterdam, The Netherlands, ²EMGO-Institute, VU University Medical Center, Amsterdam, The Netherlands, ³Department of Public Health, Erasmus University Medical Center, Rotterdam, The Netherlands, ⁴Department of General Practice, VU University Medical Center, Amsterdam, The Netherlands, ⁵Psychology & Genetics Research group, King’s College, London, United Kingdom.

EPL1.5 Illness risk representations and preventive behaviour in people diagnosed with Familial Hypercholesterolemia by DNA-testing
L. Claassen¹, L. Henneman¹, I. Kindt², T. M. Marteau³, D. R. M. Timmermans¹;
¹EMGO-Institute, Department of Public and Occupational Health, VU University Medical Center, Amsterdam, The Netherlands, ²Foundation for Tracing Hereditary Hypercholesterolemia (StOEH), Amsterdam, The Netherlands, ³Psychology & Genetics Research Group, King's College, London, United Kingdom.
 

EPL2.1 Genetic testing in asymptomatic minors: social and ethical issues
P. Borry, K. Dierickx;
Centre for Biomedical Ethics and Law, K.U.Leuven, Leuven, Belgium.

EPL2.2 Public attitudes towards genetic testing for susceptibility to major depression
A. Wilde¹, B. Meiser¹, P. B. Mitchell¹, P. R. Schofield²;
¹University of New South Wales, Sydney, NSW, Australia, ²Prince of Wales Medical Research Institute, Sydney, NSW, Australia.

EPL2.3 Exploring Psychiatric Genetics through Interactive Drama
F. Ticehurst¹, B. Williams², L. Osborn³, P. Gibbins⁴, J. Davies⁴;
¹Wales Gene Park, Cardiff, United Kingdom, ²Genetic Interest Group, Cardiff, United Kingdom, ³Freelance Writer, Cardiff, United Kingdom, ⁴Gwent Theatre Company, Abergavenny, United Kingdom.

EPL2.4 Professional ambivalence: accounts of ethical practice in childhood genetic testing
M. A. Arribas-Ayllon, S. Sarangi, A. Clarke;
Cardiff University, Cardiff, United Kingdom.
 

S03.2 Medical Genetic services in developing countries (20')
A. Christianson;
Division of Human Genetics, National Health Laboratory Services & University of the Witwatersrand, Johannesburg, South Africa. 

S03.3 Genetic testing and private companies. The US as a model for Europe? (15')
M. Aspinal;
Genzyme Corporation, Westborough, MA, United States

S03.4 Are genetic and molecular biomarkers ready for the clinic? (20')
R. Zimmern;
PHG Foundation Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom. 

EPL3.1 Patients’ attitudes to the use of preimplantation genetic diagnosis for inherited predispositions to bowel cancer
A. A. D. Melville, H. E. Musgrave, T. Clancy;
Medical Genetics Research Group and Regional Genetics Service, University of Manchester and CMMC NHS Trust, Manchester, United Kingdom.

EPL3.2 Pre-implantation genetic diagnosis (PGD) and prenatal diagnosis (PND) for cancer predisposition syndromes: reported practices and attitudes of French professionals
C. M. Julian-Reynier^1,2, F. Chabal³, F. Nowak⁴, T. Frebourg⁵, D. Lemery⁶, C. Noguès⁷, F. Puech⁸, F. Thepot⁹, D. Stoppa-Lyonnet¹⁰;
¹INSERM (UMR912), Marseille, France, ²Institut Paoli-Calmettes, Marseille, France, ³UMR912 INSERM, Marseille, France, ⁴Institut National du Cancer, Paris, France, ⁵University Hospital, Rouen, France, ⁶University Hospital, Clermont-Ferrand, France, ⁷Regional Cancer Centre, Saint-Cloud, France, ⁸University Hospital (Jeanne de Flandre Hospital), Lille, France, ⁹Agence de Biomédecine, Paris, France, ¹⁰Institut Curie, Paris, France.

EPL3.3 Motivations for genetic testing among individuals at risk of hereditary breast-ovarian cancer (HBOC) and Lynch syndromes
D. Fortuny¹, N. Gadea¹, B. Graña², T. Ramón y Cajal³, A. Torres⁴, J. Brunet², A. Velasco², E. Darder⁵, J. Sánz⁴, C. López³, J. Balmaña¹;
¹Hospital Universatario Vall d'hebrón, Barcelona, Spain, ²Medical oncology department ICO, Hospital Josep Trueta, Girona, Spain, ³Medical oncology department. Hospital de Sant Pau, Barcelona, Spain, ⁴Medical oncology department, Hospital Sant Joan, Reus, Spain, ⁵Medical oncology department ICO, Hospital Josep Trueta, Barcelona, Spain.

EPL3.4 Exploring the influence of the family social network on the psychological well-being of individuals undergoing genetic counseling and testing for Lynch syndrome
D. W. Hadley, S. Ashida, N. R. Kuhn, J. F. Jenkins, C. M. McBride, L. M. Koehly;
National Institutes of Health, Bethesda, MD, United States.

EPL3.5 Genetic counselling and testing for melanoma risk in Australia: A prospective study of uptake and psychological implications
N. A. Kasparian^1,2, B. Meiser^3,2, P. N. Butow⁴, J. M. Simpson⁵, G. J. Mann⁶;
¹School of Women's and Children's Health, University of New South Wales, Kensington, Australia, ²Department of Medical Oncology, Prince of Wales Hospital, Randwick, Australia, ³Prince of Wales Clinical School, University of New South Wales, Kensington, Australia, ⁴Medical Psychology Research Unit, School of Psychology, University of Sydney, Sydney, Australia, ⁵School of Public Health, University of Sydney, Sydney, Australia, ⁶Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead, Australia.
 

S05.1 Guidelines for the clinical management of Lynch syndrome and adenomatous polyposis (30')
H. F. Vasen;
Department of Gastroenterology & Medical Oncology, Leiden University Medical Centre, Leiden, Netherlands. 

S05.03 Managing genetic risk: Some issues for BRCA1 and 2 mutation carriers (30')
N. Hallowell;
Public Health Sciences, University of Edinburgh, Edinburgh, United Kingdom. 
 

EPL4.1 Antenatal screening for fetal abnormality - ensuring informed choice for parents
H. Skirton¹, O. Barr², J. Frost³, T. Wells¹;
¹University of Plymouth, Taunton, United Kingdom, ²University of Ulster, Belfast, United Kingdom, ³University of Plymouth, Plymouth, United Kingdom.

EPL4.2 The role of attitudinal ambivalence towards Down’s syndrome in prenatal testing decisions
L. D. Bryant¹, J. M. Green², J. Hewison¹;
¹Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom, ²Department of Health Sciences, University of York, York, United Kingdom.

EPL4.3 ‘Balance’ is in the eye of the beholder: perceptions of balanced information to support informed choices via AnSWeR (Antenatal Screening Web Resource)
S. Ahmed, L. D. Bryant, J. Hewison;
University of Leeds, LEEDS, United Kingdom.

EPL4.4 Testing times, challenging choices; women, prenatal testing and genetic counselling
J. M. Hodgson¹, M. A. R. Sahhar^1,2, L. H. Gillam^1,3, S. A. Metcalfe^1,3;
¹Murdoch Childrens Research Institute, Melbourne, Australia, ²Genetic Health Services Victoria, Melbourne, Australia, ³University of Melbourne, Melbourne, Australia.

EPL4.5 "It's something I need to consider": women's decisions about population carrier screening for fragile X syndrome
A. D. Archibald^1,2, A. M. Jaques¹, S. Wake³, S. A. Metcalfe^1,2;
¹Murdoch Childrens Research Institute, Melbourne, Australia, ²University of Melbourne, Melbourne, Australia, ³Genetic Health Services Victoria, Melbourne, Australia.
 

EPW2. Assessing Quality of Counselling in the Context of Genetic Testing Workshop
H. Skirton¹, H. Kaariainen², E. Rantanen³, M. Hietala³, J. Sequeiros⁴, U. Kristoffersson⁵, L. Kerzin-Storrar⁶, A. Tibben⁷, G. Evers-Keibooms⁸, A. Faucett⁹, A. Clarke¹⁰;
¹Faculty of Health and Social Work, University of Plymouth, Taunton, United Kingdom, ²National Public Health Institute, Helsinki, Finland, ³Department of Medical Genetics, University of Turku, Turku, Finland, ⁴IBMC, University of Porto, Porto, Portugal, ⁵Department of Clinical Genetics, University Hospital, Lund, Sweden, ⁶Regional Genetics Service & Medical Genetics Research Group, CMMC & University of Manchester, Manchester, United Kingdom, ⁷Centre for Human and Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands, ⁸Centre for Human Genetics, University of Leuven, Leuven, Belgium, ⁹Emory University School of Medicine, Atlanta, GA, United States, ¹⁰Institute of Medical Genetics, Cardiff University, Cardiff, United Kingdom.
 

EPL5.1 Verification of consumers’ experiences and perceptions of genetic discrimination and its impact on utilisation of genetic testing
K. K. Barlow-Stewart¹, S. Taylor², S. Treloar³, M. Stranger^4,5, M. Otlowski^4,5;
¹The Centre for Genetics Education, Sydney, Australia, ²Department of Social Work and Human Services, Central Queensland University, Rockhampton, Australia, ³Centre for Military and Veterans’ Health, The University of Queensland, Brisbane, Australia, ⁴Centre for Law and Genetics, University of Tasmania, Hobart, Australia, ⁵School of Law, University of Tasmania, Hobart, Australia.

EPL5.2 The Multiplex Initiative: a study to determine who seeks free multiplex genetic susceptibility testing among a healthy population of American adults
C. M. McBride¹, S. Hensley-Alford², R. Reid³, E. Larson³, A. D. Baxevanis¹, L. C. Brody¹;
¹National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States, ²Henry Ford Health System, Detroit, MI, United States, ³Group Health Cooperative, Seattle, WA, United States.

EPL5.3 Willingness for blood donation for genomic studies: a comparative study between scientists and the public
K. Muto¹, A. Nagai², A. Tamakoshi³, I. Ishiyama², K. Kato⁴, Z. Yamagata²;
¹The University of Tokyo, Tokyo, Japan, ²Yamanashi University, Yamanashi, Japan, ³Aichi Medical University, Aichi, Japan, ⁴Kyoto University, Kyoto, Japan.

EPL5.4 Privatising susceptibility to disease: the need for regulation?
A. J. Clarke¹, I. Frayling², M. Arribas-Ayllon¹, S. Sarangi¹;
¹Cardiff University, Cardiff, United Kingdom, ²University Hospital of Wales, Cardiff, United Kingdom.

EPL5.5 Gene patents and diagnostics: numbers don’t count
N. Berthels^1,2, B. Verbeure¹, E. van Zimmeren¹, G. Van Overwalle¹, G. Matthijs²;
¹Centre for Intellectual Property Rights, KULeuven, Leuven, Belgium, ²Center for Human Genetics, KULeuven, Leuven, Belgium.
 

S10.1 In utero stem cell transplantation: where are we now? (30')
T. H. Bui;
Department of Molecular Medicine, Clinical Genetics Unit, Stockholm, Sweden. 

S10.1 The regulation of prenatal and preimplantation genetic diagnosis in the UK (30')
E. Jackson;
Law Department, London School of Economics, London, United Kingdom. 

EPW4. Analysing the social dimensions of coping in families: a workshop on presenting the results in clinical practice
H. G. Van Spijker, T. Brouwer;
Medical Genetics University Medical Centre, 3508 CA Utrecht, The Netherlands.
 

EPL6.1 Psychosocial Impact of X-linked Carrier Status: Experiences of Female Adrenoleukodystrophy Carriers
J. Bowen¹, R. Mountford², L. Kerzin-Storrar³;
¹Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom, ²Department of Medical Genetics, Liverpool Women's NHS Foundation Trust, Liverpool, United Kingdom, ³Regional Genetic Service and Medical Genetics Research Group, CMMC NHS Trust and University of Manchester, Manchester, United Kingdom.

EPL6.2 The marital relationship and psychological wellbeing in patients with Myotonic Dystrophy
R. Timman¹, A. Rotteveel², A. Wintzen¹, A. Tibben²;
¹Neurology, Leiden, The Netherlands, ²Human and Clinical Genetics, Leiden, The Netherlands.

EPL6.3 Living with NF1: The persectives of young people
K. F. May¹, R. A. Collier², L. Kerzin-Storrar³;
¹West Midlands Regional Clinical Genetics Service, Birmingham, United Kingdom, ²Nottingham Regional Clinical Genetics Service, Nottingham, United Kingdom, ³North West Regional Genetics Service, Manchester, United Kingdom.

EPL6.4 Quality of life in hypertrophic cardiomyopathy mutation carriers
I. Christiaans¹, I. M. van Langen¹, E. Birnie², G. J. Bonsel², A. A. M. Wilde³, E. M. A. Smets^1,4;
¹Department of Clinical Genetics, Academic Medical Centre, Amsterdam, The Netherlands, ²Institute of Health Policy and Management, Erasmus Medical Centre, Rotterdam, The Netherlands, ³Department of Cardiology, Academic Medical Centre, Amsterdam, The Netherlands, ⁴Department of Medical Psychology, Academic Medical Centre, Amsterdam, The Netherlands.

EPL6.5 Developing a cancer genetic-specific measure of coping
C. Phelps¹, P. Bennett², H. Jones¹, K. Brain¹, K. Hood³, A. Murray⁴;
¹Institute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom, ²Nursing, Health and Social Care Research Centre; Cardiff University, Cardiff, United Kingdom, ³Centre for Health Sciences Research; Cardiff University, Cardiff, United Kingdom, ⁴Institute of Medical Genetics, University Hospital of Wales, Cardiff, Cardiff, United Kingdom.